TGTX — TG THERAPEUTICS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1001316 ·
Last close
$49.52
Market Cap
$7.58B
52W High
$50.41
52W Low
$26.93
ADV30
2,268,937
Next earnings
2026-08-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 204,918,000 | 171,408,000 | 34,795,000 | 19,777,000 | 1,528,837,000 | 442,209,000 | 945,706,000 |
| Dec 2025 | 192,574,000 | 154,432,000 | 50,494,000 | 23,037,000 | 1,063,253,000 | 79,148,000 | 415,233,000 |
| Sep 2025 | 161,709,000 | 133,616,000 | 29,365,000 | 390,895,000 | 1,025,024,000 | 74,081,000 | 417,806,000 |
| Jun 2025 | 141,148,000 | 122,210,000 | 34,843,000 | 28,187,000 | 702,613,000 | 129,126,000 | 426,181,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-24,772,000
Investing CF
$13,799,000
Financing CF
$-89,729,000
CapEx
$-214,000
Dividends Paid
—
Buybacks
$-91,240,000
EPS Diluted TTM
$2.77
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,082,015,000
Inventory
$125,586,000
Receivables
$305,628,000
ST Investments
$62,822,000
EBIT TTM
$134,117,000
Pretax Income TTM
$107,390,000
Interest Exp TTM
$26,727,000
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$700,348,992
EBITDA
$149,580,000
Free Cash Flow
$-30,164,876
Enterprise Value
$7,257,250,304
Total Cash
$514,430,016
Total Debt
$753,556,992
Shares Out
153,083,580
Trailing EPS
$2.86
Book Value
$4.11
ROE
112.6%
ROA
8.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 616,287,000 | 123,324,000 | 447,179,000 | 1,063,253,000 | 415,233,000 | — | -24,772,000 |
| Dec 2024 | 329,004,000 | 41,929,000 | 23,383,000 | 577,690,000 | 355,326,000 | — | -40,517,000 |
| Dec 2023 | 233,662,000 | 20,633,000 | 12,672,000 | 329,587,000 | 169,085,000 | — | -31,413,000 |
| Dec 2022 | 2,785,000 | -218,316,000 | -223,812,000 | 193,572,000 | 134,985,000 | — | -176,170,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$2.87
Max Pain — expiry 2026-06-18
max pain strike: $39.00 · spot: $50.30 · call oi: 11,804 · put oi: 4,505
Expected Move to 2026-06-18:
±$1.95
(3.88%) —
implied range
$48.35 –
$52.25
· ATM straddle on $50.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ABVX | Abivax S.A. | $7.69B | $96.55 | — |
| PRAX | Praxis Precision Medicines, Inc. | $7.43B | $266.58 | — |
| ALKS | Alkermes plc. | $7.38B | $44.28 | — |
| PTGX | Protagonist Therapeutics, Inc | $7.06B | $109.78 | — |
| SYRE | Spyre Therapeutics, Inc. | $7.02B | $80.79 | — |
News headlines (Yahoo Finance, 1h cache)
Dow Jones Futures Signal Market Bounce, But Then What? Oracle Dives, SpaceX IPO On Launch Pad
2026-06-11 12:10 · Yahoo
TG Therapeutics (TGTX) Soars 7.5%: Is Further Upside Left in the Stock?
2026-06-11 09:12 · Yahoo
Why This IBD Stock Of The Day, A Roche Rival, Just Broke Out To A Five-Year High
2026-06-10 20:57 · Yahoo
Why TG Therapeutics (TGTX) Is Up 18.4% After Advancing At‑Home Subcutaneous BRIUMVI In MS Treatment
2026-06-10 16:15 · Yahoo
TGTX Rises on Positive Phase I Data for Subcutaneous Briumvi in MG
2026-06-10 13:17 · Yahoo
Dow Jones Futures Tumble As Trump Says Iran Will 'Have To Pay The Price'; CPI Inflation On Tap
2026-06-10 12:08 · Yahoo
TGTX Stock Jumps 5% On Positive Early Data For At-Home BRIUMVI In Muscle Disease
2026-06-09 20:34 · Yahoo
Sector Update: Healthcare Stocks Rise Pre-Bell Tuesday
2026-06-09 13:18 · Yahoo
TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial
2026-06-09 11:30 · Yahoo
A Look At TG Therapeutics (TGTX) Valuation After Recent Positive BRIUMVI Trial Updates
2026-06-09 11:06 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.